Standish Fleming, Contributor

With the Fed talking about raising interest rates over 200 basis points or more this summer to combat the highest inflation since the 1980s and the stock market signaling a possible recession, what lies ahead for venture managers and their companies?

Is starting with $3 billion a better way to make new drugs?

The Congressional Budget Office and academic researchers ignore or misunderstand small companies when they analyze the impact of proposed price controls with potentially devastating consequences for new drug development.

Price controls on new drugs will kill innovation. Many of the treatments most urgently needed have yet to be developed.

In biopharma, the potential for new medications is increasing exponentially. Yet an unproductive business model threatens the future of the industry.

Pharma must change, but policies, like Trump’s most favored nation rule, that ignore root causes risk irreparable harm to industry and patients.

With anxiety already high over current drug supply lines, these policies would leave the country dependent on China for future medicines.

To produce more drugs, pharma must make the entrepreneurial community an integral part of R&D. …More drugs mean better drugs, expanded choice for patients and more competitive markets.

How much do new drugs cost to make, why, and what returns does industry need to sustain innovation?

Could a cooperative industry be more productive than a competitive one?